Pegfilgrastim is a recombinant human granulocyte colony-stimulating factor (G-CSF) that is primarily used to stimulate the production of white blood cells, particularly neutrophils, in patients undergoing chemotherapy. It is a pegylated form of filgrastim, which means it has been modified with polyethylene glycol (PEG) to enhance its stability and prolong its half-life in the bloodstream. This modification allows for less frequent dosing compared to non-pegylated forms. Pegfilgrastim is typically administered via subcutaneous injection and is indicated for the prevention of chemotherapy-induced neutropenia, thereby reducing the risk of infection in patients with certain types of cancer. The substance is characterized by its ability to bind to the G-CSF receptor on hematopoietic cells, promoting the proliferation and differentiation of progenitor cells in the bone marrow. Common side effects may include bone pain, injection site reactions, and, in rare cases, splenic rupture. Overall, pegfilgrastim plays a crucial role in supportive cancer care by enhancing the immune response during chemotherapy.

Pegfilgrastim

208265-92-3: Pegfilgrastim is a recombinant human granulocyte colony-stimulating factor (G-CSF) that is primarily used to stimulate the production of white blood cells, particularly neutrophils, in patients undergoing chemotherapy. It is a pegylated form of filgrastim, which means it has been modified with polyethylene glycol (PEG) to enhance its stability and prolong its half-life in the bloodstream. This modification allows for less frequent dosing compared to non-pegylated forms. Pegfilgrastim is typically administered via subcutaneous injection and is indicated for the prevention of chemotherapy-induced neutropenia, thereby reducing the risk of infection in patients with certain types of cancer. The substance is characterized by its ability to bind to the G-CSF receptor on hematopoietic cells, promoting the proliferation and differentiation of progenitor cells in the bone marrow. Common side effects may include bone pain, injection site reactions, and, in rare cases, splenic rupture. Overall, pegfilgrastim plays a crucial role in supportive cancer care by enhancing the immune response during chemotherapy.

Immunological products, mixed, not put up in measured doses or in forms or packings for retail sale

CAS 208265-92-3

Pegfilgrastim

Pegfilgrastim for Bioassay

Ref: 45-1500626